Ernst E, Dormandy J
Scand J Clin Lab Invest Suppl. 1981;156:317-9. doi: 10.3109/00365518109097501.
Arovin (ancrod) treatment is generally recognized to lower fibrinogen levels and is sometimes used to decrease plasma and whole blood viscosity. The fall in fibrinogen is accompanied by a rise in fibrinogen degradation products (FDP), but none of the other clotting factors is affected. This study shows that patients undergoing surgery with subsequent Arvin treatment decrease their red cell filterability (RCF), and that this drop cannot be explained by either the surgical intervention, a direct effect of Arvin on the red cells, or the lowered fibrinogen levels. However the decrease of RCF does correlate with the rise in FDP.
蝮蛇抗栓酶（Ancrod）治疗通常被认为可降低纤维蛋白原水平，有时用于降低血浆和全血粘度。纤维蛋白原水平下降的同时，纤维蛋白原降解产物（FDP）水平会升高，但其他凝血因子均不受影响。本研究表明，接受手术并随后接受蝮蛇抗栓酶治疗的患者，其红细胞滤过率（RCF）降低，且这种下降无法用手术干预、蝮蛇抗栓酶对红细胞的直接作用或降低的纤维蛋白原水平来解释。然而，红细胞滤过率的降低确实与纤维蛋白原降解产物的升高相关。
